← Back to home

Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid)

Clinical trials for Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid) explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid) trials appear

Sign up with your email to follow new studies for Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Promising melanoma combo trial halted early – only one patient enrolled

Disease control Stopped early

This study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safet…

Matched conditions: RELAPSED/REFRACTORY, LOCALLY ADVANCED UNRESECTABLE MELANOMA (STAGE IIIB, IIIC, OR IIID)

Phase 2 • Sponsor: Genmab • Aim: Disease control

Last updated Jul 10, 2026 00:00 UTC

Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid)

Get alerted when new Relapsed/refractory, locally advanced unresectable melanoma (stage IIIB, IIIC, or iiid) trials appear

Promising melanoma combo trial halted early – only one patient enrolled